Novo Nordisk A/S Diabetes Drug Tops Byetta in Trial

June 9, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW YORK (Reuters) - Novo Nordisk's experimental type 2 diabetes drug, liraglutide, was superior in controlling blood sugar in a clinical trial to Eli Lilly and Co and Amylin Pharmaceuticals Inc's Byetta, the Danish company said on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

Novo Nordisk